<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623684</url>
  </required_header>
  <id_info>
    <org_study_id>170/10-03-2020</org_study_id>
    <nct_id>NCT04623684</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial</brief_title>
  <official_title>Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess whether the use of microdrop instillation of phenylephrine 1.67% and&#xD;
      tropicamide 0.33% maintains mydriatic efficacy while presents an improved safety profile&#xD;
      compared with standard drops of phenylephrine 1.67% and tropicamide 0.33%, which is routine&#xD;
      care for pupil dilation during retinopathy of prematurity (ROP) screening in our neonatal&#xD;
      intensive care unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot prospective randomized crossover clinical trial is conducted for assessing the&#xD;
      mydriatic efficacy and safety of microdrops (6-7 μL) compared with standard drops (28-34 μL)&#xD;
      for retinopathy of prematurity screening. A random number table was used to allocate&#xD;
      participants into either a) receiving standard drop on their first and microdrop on their&#xD;
      second screening examination a week later, or b) receiving microdrop first and standard drop&#xD;
      a week later. The mydriatic agent contains phenylephrine 1.67% and tropicamide 0.33%, which&#xD;
      derives from compounding the commercial phenylephrine 5% with the commercial tropicamide 0.5%&#xD;
      in volume ratio 1:2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Actual">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mydriatic efficacy: mm of pupil diameter (left and right eye)</measure>
    <time_frame>45 minutes after the first drop instillation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mydriatic efficacy: mm of pupil diameter (left and right eye)</measure>
    <time_frame>90 minutes after the first drop instillation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mydriatic efficacy: mm of pupil diameter (left and right eye)</measure>
    <time_frame>120 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Heart Rate (bpm)</measure>
    <time_frame>45 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Heart Rate (bpm)</measure>
    <time_frame>90 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Heart Rate (bpm)</measure>
    <time_frame>120 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of oxygen saturation (SpO2) (%)</measure>
    <time_frame>45 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of oxygen saturation (SpO2) (%)</measure>
    <time_frame>90 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of oxygen saturation (SpO2) (%)</measure>
    <time_frame>120 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Blood Pressure (Systolic, Diastolic and Mean Blood Pressure) (mmHg)</measure>
    <time_frame>45 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Blood Pressure (Systolic, Diastolic and Mean Blood Pressure) (mmHg)</measure>
    <time_frame>90 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Blood Pressure (Systolic, Diastolic and Mean Blood Pressure) (mmHg)</measure>
    <time_frame>120 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic side effects: measurements of Blood Pressure (Systolic, Diastolic and Mean Blood Pressure) (mmHg)</measure>
    <time_frame>Hourly for the first 24 hours after mydriasis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local side effects: periorbital pallor, eyelid swelling, flushing</measure>
    <time_frame>45 minutes after the first drop instillation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events including apnea, increased gastric residuals, inhibited duodenal motor activity, delayed gastric emptying, feeding intolerance, abdominal distension, vomiting, paralytic ileus, acute gastric dilatation and necrotizing enterocolitis (NEC)</measure>
    <time_frame>During the 24 hours after mydriasis for ROP screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with non-adequate mydriasis to fully visualize peripheral fundus according to the examiner</measure>
    <time_frame>Upon eye examination (45 to 90 minutes after the first drop)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mydriasis with microdrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mydriasis with standard drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]</intervention_name>
    <description>1 drop (6-7 μL) for 3 doses, 5 minutes' intervals</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]</intervention_name>
    <description>1 drop (28-34 μL) for 3 doses, 5 minutes' intervals</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Preterm infants undergoing screening for ROP, i.e.&#xD;
&#xD;
          -  with gestational age (GA) &lt; 32 weeks and/or birth weight (BW) &lt; 1501 grams&#xD;
&#xD;
          -  infants of greater GA and BW with increased comorbidity, e.g. sepsis, prolonged need&#xD;
             for oxygen supplementation etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable clinical condition&#xD;
&#xD;
          -  Suspicion of cardiovascular disease&#xD;
&#xD;
          -  Severe congenital anomalies&#xD;
&#xD;
          -  Clinical syndromes&#xD;
&#xD;
          -  Traumatic apoptosis of the corneal epithelium&#xD;
&#xD;
          -  Corneal ulcer&#xD;
&#xD;
          -  Anatomical variations of the anterior segment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Weeks</minimum_age>
    <maximum_age>37 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Papageorpiou&quot; General Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Lynch MG, Brown RH, Goode SM, Schoenwald RD, Chien DS. Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption. Arch Ophthalmol. 1987 Oct;105(10):1364-5.</citation>
    <PMID>3662909</PMID>
  </reference>
  <reference>
    <citation>Elibol O, Alçelik T, Yüksel N, Caglar Y. The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants. Acta Ophthalmol Scand. 1997 Apr;75(2):178-80.</citation>
    <PMID>9197568</PMID>
  </reference>
  <reference>
    <citation>Seliniotaki AK, Prousali E, Lithoxopoulou M, Kokkali S, Ziakas N, Soubasi V, Mataftsi A. Alternative mydriasis techniques for retinopathy of prematurity screening. Int Ophthalmol. 2020 Dec;40(12):3613-3619. doi: 10.1007/s10792-020-01542-x. Epub 2020 Aug 9. Review.</citation>
    <PMID>32772218</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 31, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Asimina Mataftsi</investigator_full_name>
    <investigator_title>Associate Professor in Ophthalmology, Paediatric Ophthalmology and Strabismus</investigator_title>
  </responsible_party>
  <keyword>microdrops</keyword>
  <keyword>mydriasis</keyword>
  <keyword>dilating drops</keyword>
  <keyword>retinopathy of prematurity</keyword>
  <keyword>ROP</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

